A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its components for incident cardiovascular disease in Middle East Caucasian residents in Tehran

Journal of Epidemiology and Community Health

Volumn 66, Issue 5, 2012, Pages 427-432

  Hadaegh, F ^a   Zabetian, A ^a   Khalili, D ^a,b   Safarkhani, M ^a   James, W Philip T ^c,d   Azizi, F ^e  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d International Association for the Study of Obesity   (United Kingdom)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BODY SIZE; CARDIOVASCULAR DISEASE; DISEASE INCIDENCE; GENDER ROLE; GLUCOSE; HYPERTENSION; OBESITY; PREDICTION; RACE; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; COMPARATIVE STUDY; ETHNOLOGY; FEMALE; HUMAN; IRAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MIDDLE EAST; NOMENCLATURE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS;

ADULT; CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IRAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MIDDLE EAST; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TERMINOLOGY AS TOPIC;

IRAN; MIDDLE EAST; TEHRAN [IRAN];

EID: 84861189987     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2010.117697     Document Type: Article

References (32)

1. Reaven GM, Chen YD. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988;4:639-52.
2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
3. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
4. Sattar N. Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes (Lond) 2008;32(SUPPL 2):S30-4.
5. Sundstrom J, Vallhagen E, Riserus U, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006;29:1673-4.
6. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
7. Hadaegh F, Zabetian A, Sarbakhsh P, et al. Appropriate cutoff values of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an Iranian population. Int J Obes (Lond) 2009;33:1437-45.
8. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 2007;77:251-7.
9. Zabetian A, Hadaegh F, Sarbakhsh P, et al. Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. BMC Public Health 2009;9:138.
10. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
11. Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002;47:408-26.
12. Azizi F, Ghanbarian A, Momenan AA, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 2009;10:5.
13. Hadaegh F, Harati H, Ghanbarian A, et al. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil 2006;13:571-7.
14. Agresti A. An introduction to categorical data analysis. Hoboken, NJ: John Wiley & Sons, 2007:141-2.
15. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23.
16. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. Stata J 2006b;6:309-34.
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.
18. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M.J. Pencina et al., Statistics in Medicine (doi:10.1002/sim.2929). Stat Med 2008;27:191-5.
19. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without Creactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
20. Iribarren C, Go AS, Husson G, et al. Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts? J Am Coll Cardiol 2006;48:1800-7.
21. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006;49:41-8.
22. Enders FB. Colinearity. In: Boslaugh S Encyclopedia of Epidemiology. Los Angeles, CA: SAGE publications, 2008:208-9.
23. Zabetian A, Hadaegh F, Azizi F. Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women. Exp Clin Endocrinol Diabetes 2008;116:525-31.
24. Hadaegh F, Khalili D, Fahimfar N, et al. Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). J Endocrinol Invest 2009;32:724-30.
25. Hsu PF, Chuang SY, Cheng HM, et al. Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: a community-based study. Diabetes Res Clin Pract 2008;79:461-7.
26. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
27. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.
28. Azizi F, Raiszadeh F, Salehi P, et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. Nutr Metab Cardiovasc Dis 2002;12:80-9.
29. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003;34:623-31.
30. Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008;168:969-78.
31. Alberti KG, Zimmet P, Shaw J. Metabolic syndromeda new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
32. Anon. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987-92.